Abstract
The treatment for patients with lung cancer undergoing hemodialysis, who are frequently elderly and have poor performance status, becomes a more important subject. However, the feasibility of afatinib in patients with chronic renal failure undergoing hemodialysis has not, so far, been reported. Here, afatinib was administered to three patients with NSCLC harboring EGFR mutation and chronic renal failure undergoing hemodialysis. Pharmacokinetic (PK) data of afatinib supported the safety of afatinib treatment. After receiving their written informed consent from all patients, they were administered 30 mg afatinib daily with HD three times a week. We performed PK analyses of afatinib on days 1, 2, 10, and 11 after initial administration of afatinib. All three patients exhibited a partial response without any serious adverse events during the administration of afatinib. These PK data were similar to those of patients with normal organ function, which were previously reported. Our findings may be particularly useful given the current opportunity to use afatinib as a first-line treatment for EGFR-mutated NSCLC patients, providing an additional option for patients with impaired renal function.
This is a preview of subscription content, log in via an institution to check access.
References
Maisonneuve P, Agodoa L, Gellert R et al (1999) Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 354:93–99
Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957
Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121–128
Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388
Inoue A, Kobayashi K, Usui K et al (2009) First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27:1394–1400
Maemondo M, Minegishi Y, Inoue A et al (2012) First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol 7:1417–1422
Katakami N, Atagi S, Goto K et al (2013) LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 31:3335–3341
Wu YL, Zhou C, Hu CP et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15:213–222
Shinagawa N, Yamazaki K, Asahina H et al (2007) Gefitinib administration in a patient with lung cancer undergoing hemodialysis. Lung Cancer 58:422–424
Gridelli C, Maione P, Galetta D et al (2007) Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure. J Thorac Oncol 2:96–98
Togashi Y, Masago K, Fukudo M et al (2010) Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis. J Thorac Oncol 5:601–605
Del Conte A, Minatel E, Schinella D et al (2014) Complete metabolic remission with Gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer. Anticancer Res 34:319–322
Bersanelli M, Tiseo M, Artioli F et al (2014) Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis. Anticancer Res 34:3185–3188
Hayashi H, Kita Y, Iihara H et al (2016) Simultaneous and rapid determination of gefitinib, erlotinib, and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer. Biomed Chromatogr 30:1150–1154
Eskens FA, Mom CH, Planting AS et al (2008) A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 98:80–85
Yap TA, Vidal L, Adam J et al (2010) Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 28:3965–3972
Peters S, Zimmermann S, Adjei AA (2014) Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. Cancer Treat Rev 40:917–926
Yamaguchi T, Hayashi H, Isogai S et al (2015) Afatinib administration in a patient with non-small cell lung cancer harboring uncommon EGFR mutation G719A undergoing hemodialysis. Cancer Treat Commun 4:169–171
Miller AA, Murry DJ, Owzar K et al (2007) Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol 25:3055–3060
Acknowledgements
We are grateful to Ms. Yuka Matsui for her technical assistance during manuscript submission. We wish to thank all staff of the Chemotherapy Center and Laboratory Department at Hidaka Hospital (Gunma, Japan). We also wish to thank Editage (www.editage.jp) for English language editing.
Author contributions
KK provided administrative support. IN, HH helped in providing study materials or patients. All authors were involved in manuscript writing and final approval of manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
KK has received research grants and a speaker honorarium from Boehringer Ingelheim Company.
Additional information
Kyoichi Kaira and Ichiro Naruse contributed equally to this work.
Rights and permissions
About this article
Cite this article
Imai, H., Kaira, K., Naruse, I. et al. Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis. Cancer Chemother Pharmacol 79, 209–213 (2017). https://doi.org/10.1007/s00280-016-3201-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-016-3201-9